The global relapsed or refractory diffuse large B-cell lymphoma market was estimated at USD 1,500 million in 2021 and is expected to grow to roughly USD 2,200 million by 2030, with a CAGR of 4.2% over the forecast period.
A global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market research study gives insights into the market landscape and how company strategies can be developed to thrive in the industry. This research examines a wide range of elements that influence the market and industry. These factors include industry insight and critical success factors (CSFs), market segmentation, value chain analysis, industry dynamics, market drivers, market restraints, key opportunities, technology and application outlook, country and regional analysis, competitive landscape, company market share analysis, and key company profiles.
The worldwide Relapsed or Refractory Diffuse Large B-cell Lymphoma Market study provides a comprehensive background examination of the industry, including an assessment of the parental market. It thoroughly investigates the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. The report’s base year for calculation is 2021, and the historic year is 2019. This will show how the Relapsed or Refractory Diffuse Large B-cell Lymphoma Market will perform in the forecast years by defining the market definition, classifications, applications, and engagements. Granular information is thought to help clients make more informed business decisions, and the report reflects this belief.
Request a sample copy of the report – https://wemarketresearch.com/sample-request/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/904
Relapsed or Refractory Diffuse Large B-Cell Lymphoma Market
Key Company
- Karyopharm Therapeutics
- Merck & Co., Inc.
- MorphoSys, Inc.
- Novartis AG
- Bristol Myers Squibb, Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
Region Insights
Among regions, North America is expected to dominate the global relapsed or refractory diffuse large B-cell lymphoma market throughout the estimated period, owing to increased product approval by regulatory experts in the region. In September 2020, Hoffmann-La Roche Limited (Roche Canada) received market approval from Health Canada for Polivy in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who are not eligible for autologous stem cell transplantation and have received at least one prior therapy.
Key Trend
The introduction of a relapsed or refractory diffuse large B cell lymphoma medicine with advanced technology into the market is projected to boost growth in the global relapsed or refractory diffuse large B cell lymphoma market during the forecast period. For example, on July 11, 2023, Roche, a multinational healthcare company, announced that the European Commission (EC) had granted Columvi (glofitamab) conditional marketing authorization for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic chemotherapy. Columvi is now the first CD20xCD3 T-cell-engaging bispecific antibody approved in Europe for the treatment of the most prevalent and aggressive form of lymphoma after many lines of therapy.
Columvi has the potential to alter the existing standard of care in DLBCL. In addition to producing early and long-lasting responses in people with heavily pre-treated or refractory DLBCL, Columvi is intended to be administered for a set period of time, giving patients a defined end date for their treatment cycle and the potential of a treatment-free interval. It is also a chemotherapy-free, off-the-shelf therapeutic option, which means that patients do not have to wait for cell collection and genetic editing, which can take several weeks, before beginning treatment. This could be especially relevant for people with a high risk of illness progression.
Market Drivers
The overwhelming prevalence of diffuse large B-cell lymphoma is expected to drive the global relapsed or refractory diffuse large B-cell lymphoma market growth over the forecast period. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma (NHL). According to the Lymphoma Research Foundation, a philanthropic organization based in the United States, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed each year.
Expanding administrative specialists’ endorsement of treatments for relapsed or refractory diffuse large B-cell lymphoma is expected to fuel global market growth over the forecast period. Market companies are focusing on endorsements from administrative specialists as would be expected to accelerate the global relapsed or refractory diffuse large B-cell lymphoma market development.
Secure A Copy Of The Premium Research Report@ https://wemarketresearch.com/purchase/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/904?license=single
About We Market Research
We Market Research is a leading provider of comprehensive market research solutions that assist businesses in making informed decisions and staying ahead of the competition in today’s ever-changing marketplace. With our extensive knowledge and cutting-edge methods, we assist our customers in gaining deep insights into their target markets, consumers, and competitors.
Our firm understands that great business strategies are based on accurate and actionable data. That is why we specialize in conducting in-depth research and analysis across several industries, enabling our clients to identify market trends, assess demand and supply dynamics, and identify development opportunities.
Contact us
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
